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Randomized Clinical Trials Using New Technologies in
Radiation Oncology
Ethical Dilemma for Medicine and Science
Rafal Dziadziuszko, MD, PhD, and Jacek Jassem, MD, PhD
In this issue of the Journal of Thoracic Oncology, Dr. Roelofs et al. present the resultsof multicenter comparative planning study of 25 consecutive stage I–IIIA non-small cell
lung cancer (NSCLC) patients with the use of three-dimensional conformal photon
(3DCRT), intensity modulated photon (IMRT), and passive scattered proton radiotherapy
(ROCOCO study).1 The patients were scanned with four-dimensional 18F-fluorodeoxy-
glucose-positron emission tomography/computed tomography and targets were delineated
at the Department of Radiation Oncology, Maastricht University. Subsequently, partici-
pating centers used their own treatment planning systems according to predefined criteria
and reported their plans through a centralized database. The results are shown according
to two scenarios—with prescribed dose of 70 Gy in 35 fractions to planning target volume
and by adapting the fraction dose to fulfill the toxicity criteria for organs at risk (isotoxic
dose escalation per fraction).
This and other in silico trials in radiotherapy raise several important issues. Rapid
technological progress in diagnostic and therapeutic use of radiation allows for more
accurate treatment planning and higher dose delivery to the tumor. This often leads to
change in standard of care without documenting the benefit of the innovative intervention
by conclusive phase III trial—a widely accepted golden standard in the era of evidence-
based medicine. Indeed, radiation oncologists are tempted to rely on better dose distri-
bution within the tumor volumes and on assuming the benefit from known dose-response
relationships if exposure to organs at risk may be reduced. The widespread introduction
of IMRT to clinical practice in head and neck, prostate, and many other cancers serves as
a good example. A review of clinical evidence for IMRT has identified 61 comparative
prospective studies, including only six randomized controlled trials, powered mostly for
comparison of toxicity and not efficacy.2 Most of these studies became available when
many radiation oncology departments already adopted IMRT. Not surprisingly, acute and
late toxicity has consistently been shown to be improved with IMRT, whereas the benefit
in local control or health-related quality of life has been less apparent. The limited number
of randomized studies addressing the benefit of new technologies in radiotherapy under-
lines the difficulties in performing such studies. Is randomization ethical in the case of
clearly worse dose distribution to organs at risk? Should dose escalation to the tumor be
performed with new radiotherapy techniques when dose constraints for organs at risk are
fulfilled? Prospective assessment of outcome measures remains extremely important,
particularly when fundamentally different innovative radiation technologies, such as
proton therapy, are applied. The benefits in efficacy, toxicity, and quality of life endpoints
should be quantified to better understand the magnitude of benefit and also for incremental
cost-effectiveness analyses.
The ROCOCO study provides several important findings. The authors should be
complimented for their multi-institutional collaboration in careful modeling of potential
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benefit from proton therapy and IMRT as compared with
3DCRT. Even if proton therapy plans are associated with
better dose distribution to organs at risk in most patients, this
treatment may not be applicable for all, and it is difficult to
clearly foresee which technology would suit better to partic-
ular clinical situations. With the use of proton therapy,
esophageal toxicity, already being a dose limiting toxicity in
many patients administered photon (chemo)radiation, may
become a real concern. Proton therapy, and also IMRT, opens
the room for dose escalation without increasing overall treat-
ment time and thus provides a potential for improvement of
local control and survival. The enthusiasm of safe dose
escalation to the tumor volume with proton therapy to opti-
mize local control should, however, be tempered by the fact
that most relapses in stage II and III NSCLC patients will
appear at distant sites, which together with comorbidities
constitute substantial competing risks for survival. Thus, the
ultimate benefit from proton therapies in NSCLC patients
remains to be proven in prospective controlled trials using as
comparators alternative technologies, such as 3DCRT and
IMRT, and also volumetric modulated arc therapy, which
gains increased attention in NSCLC.3 Although most radia-
tion oncologists will agree that “more is better” in terms of
safe dose delivery to the tumor, a recent closure of high-dose
arms for futility reasons in the RTOG 0617 four-arm trial
comparing in stage III NSCLC 60 Gy and 74 Gy conformal
radiotherapy combined with carboplatin and paclitaxel with
or without cetuximab (http://www.clinicaltrials.gov/ct2/
show/NCT00533949?termrtog0617) calls for particular
attention when assessing the benefit from dose escalation in
lung cancer.
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